Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous immune globulins: an update for clinicians.

× No keyword cloud information.

25 in total

1. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.

Authors: D Singh-Grewal; A Kemp; M Wong
Journal: Arch Dis Child Date: 2006-04-25 Impact factor: 3.791

Review 2. Intravenous immunoglobulin: adverse effects and safe administration.

Authors: Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal: Clin Rev Allergy Immunol Date: 2005-12 Impact factor: 8.667

3. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients.

Authors: Patricia A Taylor; Michael J Ehrhardt; Matthew M Roforth; Jessica M Swedin; Angela Panoskaltsis-Mortari; Jonathan S Serody; Bruce R Blazar
Journal: Blood Date: 2006-10-03 Impact factor: 22.113

Review 4. Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors: Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal: Int J Hematol Date: 2007-05 Impact factor: 2.490

5. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.

Authors: D Piguet; C Tosi; J-M Lüthi; I Andresen; O Juge
Journal: Clin Exp Immunol Date: 2008-01-28 Impact factor: 4.330

Review 6. The demand for polyvalent immunoglobulins in Italy.

Authors: Fabio Candura; Monica Lanzoni; Gabriele Calizzani; Samantha Profili; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno; Giuliano Grazzini
Journal: Blood Transfus Date: 2013-09 Impact factor: 3.443

7. Recommendations for the use of albumin and immunoglobulins.

Authors: Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal: Blood Transfus Date: 2009-07 Impact factor: 3.443

8. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.

Authors: Mark Ballow; Paul J Pinciaro; Timothy Craig; Gary Kleiner; James Moy; Hans D Ochs; John Sleasman; William Smits
Journal: J Clin Immunol Date: 2016-06-08 Impact factor: 8.317

9. 9 Human Immunoglobulins.

Authors:
Journal: Transfus Med Hemother Date: 2009 Impact factor: 3.747

10. Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls.

Authors: Delgertsetseg Chuluundorj; Scott A Harding; David Abernethy; Anne Camille La Flamme
Journal: Immunol Cell Biol Date: 2016-10-03 Impact factor: 5.126